leadf
logo-loader
viewAridis Pharmaceuticals Inc

Aridis Pharmaceuticals reveals exciting preclinical data for its inhaled coronavirus treatment

Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) CEO Vu Truong tells Proactive the San Jose, California-based biopharmaceutical company revealed positive pre-clinical efficacy data for its inhaled treatment for coronavirus patients.

Truong says this particular treatment is an exciting therapy because it has the potential for patients to self-medicate with an asthma inhaler where the drug is delivered directly to the infection site.

Quick facts: Aridis Pharmaceuticals Inc

Price: 6.93 USD

NASDAQ:ARDS
Market: NASDAQ
Market Cap: $69.76 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

FansUnite Entertainment pleased Canada taking a look at allowing single...

FansUnite Entertainment (CSE: FANS- OTCQB: FUNFF) President Darius Eghdami joined Steve Darling from Proactive with news the company is hailing the Canadian government’s decision to introduce legislation that would legalize single-event sports betting in Canada. Eghdami talks about why that...

2 days, 5 hours ago

2 min read